sur Quantum Biopharma Ltd.
Quantum Biopharma Reports Financial and Clinical Progress for 2024
Quantum Biopharma Ltd. has announced its financial results for 2024, showing a cash increase to $12.1 million USD compared to $11.1 million USD in 2023. Operating expenses dropped by over 32%, from $23.8 million USD in 2023 to $16.1 million USD. Net loss improved by 18%, reducing to $14.9 million USD from $18.2 million USD in 2023.
The clinical advancement involved a Phase 1 trial of Lucid-21-302 for multiple sclerosis, which revealed no safety concerns. The company initiated a toxicology study and is preparing an FDA submission for 2025. Strategic steps include expanding cryptocurrency holdings and dual listing on Upstream to attract a global investor base.
Corporate highlights feature the launch and growing sales of the unbuzzd dietary supplement. Additionally, a $2.5 million USD financing was closed, and collaborations anticipate market expansions in Puerto Rico and the Caribbean.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Quantum Biopharma Ltd.